Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study
Amedeo Capetti(Luigi Sacco Hospital), Giuliano Rizzardini(Luigi Sacco Hospital), Gaetana Sterrantino(University of Florence), Elena Mazzotta(University of Chieti-Pescara), Simona Landonio(ASST Fatebenefratelli Sacco), Alessandro Soria(University of Milano-Bicocca), Benedetto Maurizio Celesia(Ospedale Garibaldi), Laura Carenzi(Luigi Sacco Hospital), Giuseppe Vittorio De Socio(University of Perugia), Paola Meraviglia(Luigi Sacco Hospital), Marianna Meschiari(Azienda Ospedaliero-Universitaria di Modena), Elena Ricci(Mario Negri Institute for Pharmacological Research), Michele Trezzi(Ospedale Santa Maria), Barbara Menzaghi(Ospedale di Circolo di Busto Arsizio), Marco Franzetti, Adriana Ammassari(Università Cattolica del Sacro Cuore), Sergio Lo Caputo(Ospedale Santa Maria Annunziata), Giovanni Francesco Pellicanò(University of Messina), Sara Melzi(Luigi Sacco Hospital), Lolita Sasset(Ospedale Santa Maria della Misericordia di Rovigo), Antonio Di Biagio
Cited by 17
Related Papers
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
|The Lancet Rheumatology|2020|998
Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia
|Nature Communications|2020|846
Self-Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2001|470
Hospital-Acquired Infections in Critically Ill Patients With COVID-19
|CHEST Journal|2021|404